Kathleen LaPorte Net Worth

The estimated Net Worth of Kathleen Laporte is at least $75.1 mil dollars as of 17 July 2023. Ms. Laporte owns over 12,500 units of Precipio Inc stock worth over $75,126 and over the last 6 years she sold PRPO stock worth over $0. In addition, she makes $0 as Independent Director at Precipio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. LaPorte PRPO stock SEC Form 4 insiders trading

Kathleen has made over 1 trades of the Precipio Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she exercised 12,500 units of PRPO stock worth $33,000 on 17 July 2023.

The largest trade she's ever made was exercising 12,500 units of Precipio Inc stock on 17 July 2023 worth over $33,000. On average, Kathleen trades about 694 units every 0 days since 2018. As of 17 July 2023 she still owns at least 12,500 units of Precipio Inc stock.

You can see the complete history of Ms. Laporte stock trades at the bottom of the page.

Kathleen LaPorte biography

Kathleen D. LaPorte is Independent Director of the Company. Ms. LaPorte is an executive and VC with 30 years experience building innovative life sciences companies. She served as general partner with Sprout Group from 1993-2004 and was one of the founders of New Leaf Venture Partners. She is a co-founder of Health Tech Capital, a group of healthcare technology focused private and corporate investors. Ms. LaPorte served as chief business officer and later as CEO of Nodality, an immuno-oncology diagnostics company. She has served on numerous private and public company boards with roles on audit, compensation, and nominating committees. Ms. LaPorte has a B.S. in biology from Yale University and an MBA from Stanford University Graduate School of Business.

How old is Kathleen LaPorte?

Kathleen LaPorte is 56, she's been the Independent Director of Precipio Inc since 2018. There are 2 older and 6 younger executives at Precipio Inc. The oldest executive at Precipio Inc is Richard Sandberg, 77, who is the Director.

What's Kathleen LaPorte's mailing address?

Kathleen's mailing address filed with the SEC is C/O PRECIPIO, INC., 4 SCIENCE PARK, NEW HAVEN, CT, 06511.

Insiders trading at Precipio Inc

Over the last 7 years, insiders at Precipio Inc have traded over $449,545 worth of Precipio Inc stock and bought 88,796 units worth $87,860 . The most active insiders traders include Randal J Kirk, Ronald Asbury Andrews y Richard A Sandberg. On average, Precipio Inc executives and independent directors trade stock every 54 days with the average trade being worth of $44,781. The most recent stock trade was executed by Richard A Sandberg on 20 January 2023, trading 20,000 units of PRPO stock currently worth $15,600.

What does Precipio Inc do?

precipio is a cancer diagnostics reference laboratory, delivering the latest in advanced diagnostics and personalized medicine. our goal is to assist oncologists in providing the best care for their patients. at the intersection of academia, cancer research, and diagnostics, we connect physicians with world-renown pathologists at the yale school of medicine. at precipio, our customers and their patients benefit from the most accurate, expert diagnosis. we provide our customers exclusive access to some of the most innovative tests in the field of molecular diagnostics, developed through cutting edge research, and the ongoing pursuit and refinement of the science of personalized medicine.

Complete history of Ms. Laporte stock trades at Precipio Inc y 89bio Inc

Precipio Inc executives and stock owners

Precipio Inc executives and other stock owners filed with the SEC include:

• Ilan Danieli,
  Founder, Pres, CEO & Director
• Carl R. Iberger,
  CFO & Sec.
• Ayman Mohamed M.D.,
  Sr. VP of R&D and Laboratory Operations
• Ahmed Zaki Sabet,
  Chief Operating Officer
• Kathleen LaPorte,
  Independent Director
• Jeffrey Cossman,
  Independent Director
• Richard Sandberg,
  Director
• Mark Rimer,
  Director
• David Cohen,
  Director
• Ori Karev,
  Chief Strategy Officer
• Douglas Sites,
  Vice President - Sales
• Carl Iberger,
  Chief Financial Officer
• Ilan Danieli,
  President, Chief Executive Officer, Director
• Douglas Fisher,
  Interim Chairman of the Board
• Miri Chiko-Radomski,
  Gen. Counsel
• Ronald Asbury Andrews,
  Director
• Randal J Kirk,
  10% owner
• Robert Patzig,
  Director
• Samuel D Riccitelli,
  Director
• Michael A Luther,
  Director
• Ahmed Zaki Sabet,
  Chief Operating Officer
• Christina Rizopoulos Valauri,
  Director
• Matthew Gage,
  Chief Financial Officer